Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orvepitant for Pruritus in Atopic Dermatitis
NCT03464526Phase 2Withdrawn
- Sponsor
- NeRRe Therapeutics
- Start
- May 2018
- Primary completion
- Jun 2019
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of orvepitant in pruritus, sponsored by NeRRe Therapeutics. Planned start May 2018; status: withdrawn.
02
Drugs
orvepitant
03
Conditions
pruritus
Beyond the preview
Go deeper on NCT03464526.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03464526.